We look forward to welcoming you to the PREDiCT: Tumor Models Boston Summit this July 13-15.

Please see our COVID-19 update here.

 

Advancing Your Preclinical Models to Nail Targeted Immunotherapies Drug Discovery, Development & Safety Profiling

Part of the PREDiCT series, the 8th Annual PREDiCT: Tumor Models Boston Summit continues to be your only dedicated meeting for preclinical and translational scientists looking to improve early stage candidate decision making. Joining us for the 8th year pharma, biotech and academic leaders will gather this July to share their pre-clinical work and how they are harnessing emerging platforms to ensure first-in-human trials. Together, we will actively seek to improve our tumor models, accelerate drug discovery and molecule and refine your strategies to enhance translation and reduce tumor resistance.

Why you won’t want to miss the Summit:

Preclinical & Translational Oncology Leaders will explore how to optimize cost, efficacy and putting patient safety first by using preclinical models to proof and test
For 3 days, 100+ senior level scientists are set to review the challenges and opportunities of preclinical models, in aid of refining your strategies to enter clinical trials with higher success
We’ll explore how classical and emerging models are evolving efficacy determination, biomarker discovery and combination therapies, allowing you to further develop your research and gain the best insight of the industry

 

Leverage Pre-Clinical Mouse Models to Enhance Personalized Therapies and Quantify the Risk of Tumor Metastasis: Exploring the successes of classical models

 

 

 

Explore the Differences Between Disease Requirements: Understanding the importance of disease differentiation

 

 

Model the Immune Suppressive Tumor Microenvironment in vitro: Enhance and accelerate target discovery by harnessing the TM 

 

Dana Farber Cancer Institute
reviews the development
of metastatic cancel models for acute sensitivity testing

2020 Partners

LEAD PARTNER 

Crown Bio Partner Logo PREDiCT Tumor Models Boston